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The physiological cholesterol-lowering benefits of β-glucan have been well documented,
however, whether modulation of gut microbiota by β-glucan is associated with these
physiological effects remains unknown. The objectives of this study were therefore
to determine the impact of β-glucan on the composition of gut microbiota in mildly
hypercholesterolemic individuals and to identify if the altered microbiota are associated
with bioactivity of β-glucan in improving risk factors of cardiovascular disease (CVD).
Using a randomized, controlled crossover study design, individuals received for 5-week
either a treatment breakfast containing 3 g high molecular weight (HMW), 3 g low
molecular weight (LMW), 5 g LMW barley β-glucan, or wheat and rice. The American
Heart Association (AHA) diet served as the background diet for all treatment groups.
Phases were separated by 4-week washout periods. Fecal samples were collected
at the end of each intervention phase and subjected to Illumina sequencing of 16S
rRNA genes. Results revealed that at the phylum level, supplementation of 3 g/d HMW
β-glucan increased Bacteroidetes and decreased Firmicutes abundances compared to
control (P < 0.001). At the genus level, consumption of 3 g/d HMW β-glucan increased
Bacteroides (P < 0.003), tended to increase Prevotella (P < 0.1) but decreased Dorea
(P < 0.1), whereas diets containing 5 g LMW β-glucan and 3 g LMW β-glucan failed to
alter the gut microbiota composition. Bacteroides, Prevotella, and Dorea composition
correlated (P < 0.05) with shifts of CVD risk factors, including body mass index,
waist circumference, blood pressure, as well as triglyceride levels. Our data suggest
that consumption of HMW β-glucan favorably alters the composition of gut microbiota
and this altered microbiota profile associates with a reduction of CVD risk markers.
Together, our study suggests that β-glucan induced shifts in gut microbiota in a MW-
dependent manner and that might be one of the underlying mechanisms responsible for
the physiological benefits of β-glucan.
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INTRODUCTION
Mixed-linkage (1−→3)(1−→4)-β-D-glucan (β-glucan) is a linear
polysaccharide composed of D-glucose monomers joined by
(1−→4)-glycosidic bonds (∼70%) with an occasional (1−→3)-
glycosidic bonds (∼30%; Wood et al., 1991). β-glucan is the
major soluble ﬁber in oat and barley (Johansson et al., 2008)
and has shown to have physiological beneﬁts including plasma
cholesterol lowering (AbuMweis et al., 2010a; Whitehead et al.,
2014), reduction of postprandial glycaemic responses (Braaten
et al., 1991; Tappy et al., 1996; Jenkins et al., 2002), and weight
management via increasing satiety (Maki et al., 2010; Cook et al.,
2014). Previous investigations into the mechanisms underlying
these beneﬁcial eﬀects are limited to the action of β-glucan in
the upper gastrointestinal (GI) tract; however, since humans lack
enzymes for the digestion of β-glucan and other dietary ﬁbers, the
majority of these compounds are fermented in the lower GI tract
via carbohydrate active enzymes (CAZymes) produced by gut
microbiota, potentially resulting in compositional and functional
shifts in the microbiome (Cantarel et al., 2012; Chassard and
Lacroix, 2013).
Gut microbiota have long been recognized to contribute to
host nutrition and energy metabolism via production of short
chain fatty acids, amino acids, and vitamins (Morowitz et al.,
2011). The microbial-derived metabolites can be distributed well
beyond the GI tract and inﬂuence the physiology of the host,
enabling this complex network of microorganisms to act as a
virtual endocrine organ, hence, playing an important role in
host health and disease status (Fujimura et al., 2010; Sekirov
et al., 2010). Altered gut microbiota has been associated with
metabolic disorders, including obesity (Ley et al., 2006; Ley,
2010; Sanz et al., 2010; Shen et al., 2013), diabetes (Karlsson
et al., 2013; Shen et al., 2013) and cardiovascular disease (CVD;
Wang et al., 2011; Karlsson et al., 2012; Koeth et al., 2013).
Current reports suggest that manipulation of gut microbiota
toward enhancing the proportion of beneﬁcial members of the
community is a promising strategy for prevention or treatment
of metabolic diseases (Fujimura et al., 2010; Karlsson et al., 2013;
Shoaie et al., 2013). Mixed-linkage β-glucan as a fermentable
dietary ﬁber (Rose and Hamaker, 2011) could actively impact
the microbiota as exhibited from in vitro fermentation (Hughes
et al., 2008) and in vivo intervention studies (Pieper et al.,
2008; Mitsou et al., 2010). However, conclusions with regard
to the impact of β-glucan on the microbiota composition and
function are still obscure due to inconsistencies in study design,
experimental models and most importantly methodologies used
for bacterial community analyses. A well-designed clinical trial
and an appropriate methodology for global bacterial community
analysis, thus are required to provide comprehensive information
concerning quantiﬁcation of the shifts in the gut microbiota
following β-glucan consumption in humans.
It is important to note that physiochemical properties of
β-glucan, such as molecular weight (MW), are considered to
be critical factors in its physiological properties (Wood, 2002;
Wolever et al., 2010). The extent of β-glucan fermentation in the
distal GI tract may also depend on its physiochemical structure
(Hughes et al., 2008). Yet, whether β-glucan with low or high
MW alters gut microbiota in a diﬀerential manner is unknown.
In this study, we aimed to investigate whether consumption
of barley β-glucan alters the composition of gut microbiota as
represented by the feces (Krause and Khaﬁpour, 2010; Santiago
et al., 2014) and whether the alteration is in a MW dependent
manner. Also, we aimed to predict shifts in the functional
properties of the gut microbiome following barley β-glucan
consumption and to examine whether shifts in gut microbiome
composition associate with physiological eﬀects resulting from
β-glucan consumption.
MATERIALS AND METHODS
A randomized, single-blinded, controlled crossover trial was
conducted at the Clinical Nutrition Research Unit at the
Richardson Centre for Functional Foods and Nutraceuticals
(RCFFN), University of Manitoba (Winnipeg, MB, Canada) in
accordance with the principles expressed in the Declaration
of Helsinki. All research procedures were approved by the
University of Manitoba Biomedical Research Ethics Board (Ethic
reference no. B2010:057). The clinical trial was registered with
ClinicalTrials.gov (ID NCT01408719). The endpoint data for
body weight, BMI, waist circumference, blood glucose and lipid
proﬁles, and blood pressure for the 19 subjects included in this
microbiome study extracted from the parallel clinical trial that
focused on cholesterol lowering eﬀect of β-glucan (Wang et al.,
2016) and were reinterpreted in the context of their correlations
with microbial changes evaluated in this research.
Subjects
Male and female subjects aged 27–78 years (n = 30) with a body
mass index (BMI; in kg/m2) between 20 and 40 were selected
on the basis of fasting serum total cholesterol (TC) between
5.0 and 8.0 mmol/L and LDL cholesterol (LDL-C) between
2.7 and 5.0 mmol/L. Potential volunteers were excluded using
criteria including: intake of blood lipid lowering medications,
herbal or nutritional supplements which are known to aﬀect
blood lipids and any dietary restrictions which would aﬀect trial
completion. No antibiotics intake was reported at the time of
screening. A study physician evaluated the health history of
volunteers before they were accepted as subjects. The physician
also provided medical supervision throughout the study. Written
informed consent was obtained from all subjects. Of the 30
subjects in this study, a subset of 19 subjects who completed
the entire protocol and provided fecal samples for all four study
phases were selected for the microbiota proﬁle analysis.
Study Design and Experimental Diets
As described in the parallel study (Wang et al., 2016), the human
clinical trial consisted of four 5-week study phases separated by 4-
week washout periods. Subjects were randomized to one of four
experimental diets in each phase: (a) a wheat and rice (WR) based
control; (b) 3 g low molecular weight (LMW) barley β-glucan
(288 kDa); (c) 5 g LMW barley β-glucan (292 kDa); and (d)
3 g high molecular weight (HMW) barley β-glucan (1,349 kDa).
Each subject received all four treatments during the study in
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randomized orders. The barley treatments were incorporated
into breakfast in the format of crepes, tortillas, porridge, and
chips. WR were used to replace barley in breakfast as a control.
Lunch and dinner were designed using a 7-day rotating menu
to provide daily energy needs. Energy requirements of each
subject were estimated based on age, gender, body weight, and
physical activity levels and adjusted proportionately in 300 kcal
increments. Macronutrient proﬁles of treatment diets provided
approximately 30% of energy as fat, 55% as carbohydrate, and
15% as protein. Subjects consumed their intervention breakfast
meals under supervision at the clinical unit at the RCFFN
on weekdays to ensure compliance. Remaining weekday and
weekend meals including intervention breakfast were packed
for home consumption and empty containers were returned to
ensure compliance.
Body weight was monitored everyday on weekdays at
the clinical unit prior to breakfast. Waist circumference was
measured at the beginning and at the end of each intervention
phase. Fasting serum and plasma samples were collected on days
1, 2, 34 and 35. Serum TC, HDL cholesterol (HDL-C), LDL-C,
and triglyceride (TG) levels were measured. Approximately 15 g
of stool samples were collected at the end of each phase between
days 30 and 35. Subjects were advised to collect stool samples
from three locations of one bowel movement and immediately
store the collected samples in their household –20◦C freezer.
Upon transport, samples were transferred to chilled coolers and
then stored for future analysis at –80◦C.
DNA Extraction and Quality Check
Stool samples from diﬀerent phases of the projects were
DNA extracted and sequenced at once. For DNA extraction,
approximately 200 mg of each fecal sample was used for
DNA extraction using ZR Fecal DNA MiniPrepTM (Zymo
Reseach, Irvine, CA, USA), which included a bead-beating
step for the mechanical lysis of the microbial cells. DNA
was quantiﬁed using a NanoDrop 2000 spectrophotometer
(Thermo Scientiﬁc, Waltham, MA, USA). DNA samples
were normalized to 20 ng/μl, and quality checked by PCR
ampliﬁcation of the 16S rRNA gene using universal primers
27F (5′-GAAGAGTTTGATCATGGCTCAG-3′) and 342R (5′-
CTGCTGCCTCCCGTAG-3′) as described by Khaﬁpour et al.
(2009). Amplicons were veriﬁed by agarose gel electrophoresis.
Library Construction and Illumina
Sequencing
Library construction and Illumina sequencing were performed
as described by Derakhshani et al. (2015). In brief, the V4 region
of 16S rRNA gene was targeted for PCR ampliﬁcation using
modiﬁed F515/R806 primers (Caporaso et al., 2012). The reverse
PCR primer was indexed with 12-base Golay barcodes allowing
for multiplexing of samples. PCR reactions were performed in
duplicate for each sample and contained 1.0μl of pre-normalized
DNA, 1.0 μl of each forward and reverse primers (10 μM), 12 μl
HPLC grade water (Fisher Scientiﬁc, Ottawa, ON, Canada) and
10 μl 5 Prime Hot MasterMix R© (5 Prime, Inc., Gaithersburg,
MD, USA). Reactions consisted of an initial denaturing step
at 94◦C for 3 min followed by 35 ampliﬁcation cycles at 94◦C
for 45 s, 50◦C for 60 s, and 72◦C for 90 s; ﬁnalized by an
extension step at 72◦C for 10 min in an Eppendorf Mastercycler R©
pro (Eppendorf, Hamburg, Germany). PCR products were
then puriﬁed using a ZR-96 DNA Clean-up KitTM (ZYMO
Research, Irvine, CA, USA) to remove primers, dNTPs and
reaction components. The V4 library was then generated by
pooling 200 ng of each sample, quantiﬁed by Picogreen dsDNA
(Invitrogen, Burlington, ON, Canada). This was followed by
multiple dilution steps using pre-chilled hybridization buﬀer
(HT1; Illumina, San Diego, CA, USA) to bring the pooled
amplicons to a ﬁnal concentration of 5 pM, measured by an
Qubit R© 2.0 Fluorometer (Life technologies, Burlington, ON,
Canada). Finally, 15% of PhiX control library was spiked into
the amplicon pool to improve the unbalanced and biased
base composition, a known characteristic of low diversity 16S
rRNA libraries. Customized sequencing primers for read1 (5′-
TATGGTAATTGTGTGCCAGCMGCCGCGGTAA-3′), read2
(5′-AGTCAGTCAGCCGGACTACHVGGGTWTCTAAT-3′)
and index read (5′-ATTAGAWACCCBDGTAGTCCGGCTGAC
TGACT-3′) were synthesized and puriﬁed by polyacrylamide
gel electrophoresis (Integrated DNA Technologies, Coralville,
IA, USA) and added to the MiSeq Reagent Kit v2 (300-cycle;
Illumina, San Diego, CA, USA). The 150 paired-end sequencing
reaction was performed on a MiSeq platform (Illumina, San
Diego, CA, USA) at the Gut Microbiome and Large Animal
Biosecurity Laboratories, Department of Animal Science,
University of Manitoba, Canada. All sequencing data are
uploaded into the Sequence Read Archive (SRA) of NCBI and
are available through accession number SRR2558312.
Bioinformatic Analyses
Bioinformatic analyses were performed as described by
Derakhshani et al. (2015). In brief, the PANDAseq assembler
(Masella et al., 2012) was used to merge overlapping paired-end
Illumina fastq ﬁles. Sequences with mismatches or ambiguous
calls in the overlapping region were discarded. The output fastq
ﬁle was then analyzed by downstream computational pipelines
of the open source software package QIIME (Caporaso et al.,
2010b). Assembled reads were de-multiplexed according to the
barcode sequences and exposed to additional quality-ﬁlters so
that reads with more than three consecutive bases with quality
scores below 1e – 5 were truncated, and those with a read length
shorter than 75 bases were removed from the downstream
analysis. Chimeric reads were ﬁltered using UCHIME (Edgar
et al., 2011) and sequences were assigned to operational
taxonomic units (OTU) using the QIIME implementation of
UCLUST (Edgar, 2010) at 97% pairwise identity threshold.
Taxonomies were assigned to the representative sequence of
each OTU using RDP classiﬁer (Wang et al., 2007) and aligned
with the Greengenes Core reference database (DeSantis et al.,
2006) using PyNAST algorithms (Caporaso et al., 2010a). The
phylogenetic tree was built with FastTree 2.1.3. (Price et al., 2010)
for further comparisons betweenmicrobial communities. Finally,
the open source software PICRUSt (Phylogenetic Investigation of
Communities by Reconstruction of Unobserved States, version
1.0.0) was used to predict metagenome function based on 16S
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rRNA gene sequences (Langille et al., 2013). For the PICRUSt
analysis, closed-reference OTUs were picked at 97% similarity
against the Greengenes database. The OTUs were normalized for
predicted 16S rRNA copy number before predicting gene family
abundance for each metagenome based on KEGG orthology
groups (KOs) using the Kyoto Encyclopedia of Genes and
Genomes (Langille et al., 2013).
Alpha- and β-Diversity Measurements
Within community diversity (α-diversity) was calculated
using QIIME. The α rarefaction curve was generated using
Chao1 estimator of species richness (Chao, 1984) with 10
sampling repetitions at each sampling depth. An even depth
of approximately 3,984 sequences per sample was used for
calculation of richness and diversity indices. To compare
microbial composition between samples, β-diversity was
measured by calculating the weighted and unweighted UniFrac
distances (Lozupone and Knight, 2005) using QIIME default
scripts. Principal coordinate analysis (PCoA) generated two-
dimensional plots using PRIMER v6 software using resulting
distance matrices (Clarke and Gorley, 2006).
Statistical Analysis
Statistical analyses were performed as described by Li et al.
(2012) and Derakhshani et al. (2015). Non-normally distributed
data were Box–Cox transformed and then used to assess the
eﬀect of experimental diet using MIXED procedure of SAS
version 9.2 (SAS Institute Inc., Cary, NC, USA). Changes
of α-diversity indices (Chao1, Good’s coverage, Shannon and
Simpson, Observed species) were tested using a MIXED
procedure of SAS. Diﬀerential abundances in bacterial phyla and
genera were tested using MIXED and GLIMMIX procedures
of SAS, with treatment, phase and phase × treatment as ﬁxed
factors. For non-normally distributed data, Poisson and negative
binomial distributions were ﬁtted in the GLIMMIX procedure of
SAS. A log link function was speciﬁed for Poisson and negative
binomial distributions. The goodness of ﬁt for each distribution
was compared using Pearson chi-square/DF value (closer to 1 is
better) and used for selection of best distribution. Subjects were
treated as a random factor and the correlation between repeated
measures of these individuals was modeled using the ﬁrst-order
autoregressive (AR-1) option. Pairwise comparisons among the
groups were tested using Tukey studentized range adjustment.
The diﬀerences between groups were considered signiﬁcant at
P < 0.05 while trends were observed at P < 0.1.
Permutational multivariate analysis of variance (PERMA
NOVA; Anderson, 2005) was used to calculate P-values and
test for signiﬁcant diﬀerences of β-diversity among treatment
groups. The eﬀects of treatment, period, and treatment by period
interaction were considered ﬁxed factors and subject as the
random factor.
Partial least square discriminant analysis (PLS-DA; SIMCA
P+ 13.0, Umetrics, Umea, Sweden) was performed on genus
data to identify the eﬀects of treatments (Figure 2). The PLS-
DA is a particular case of partial least square regression analysis
in which Y is a set of variables describing the categories of a
categorical variable on X. In this case, X variables were bacterial
genera and Y variables were experimental diets. For this analysis,
data were scaled using Unit Variance in SIMCA. Cross-validation
was then performed to determine the number of signiﬁcant PLS
components and a permutation testing was conducted to validate
the model. To avoid over-parameterization of the model, variable
inﬂuence on projection value (VIP) was estimated for each genus
and genera with VIP < 0.50 were removed from the ﬁnal model
(Pérez-Enciso and Tenenhaus, 2003; Verhulst et al., 2011). An
R2 estimate then was used to evaluate the goodness of ﬁt and
a Q2 estimate was used to evaluate the predictive value of the
model. The PLS-regression coeﬃcients were used to identify
genera that were most characteristics of each treatment group.
The signiﬁcant shifts of taxa were determined when the error
bars of each component was above or below x axis of coeﬃcient
plot. The results of PLS-DA were visualized by PLS-DA loading
scatter plots. Figure 2 presents the PLS-DA comparisons only
between those treatments that were signiﬁcantly diﬀerent in
β-diversity.
Welch’s t-test was applied on gene function from PICRUSt
outputs, percentage of the predicted metagenome made by
a given KEGG functional module, to compare diﬀerences in
predicted metagenomic functions between treatment groups.
Correlations between bacterial taxa and clinical parameters
were performed using non-parametric Spearman’s rank
correlation (JMP, Version 10; SAS Institute Inc., Cary, NC, USA).
The clinical parameters and bacterial taxa deﬁned as response
(Y) variables and a multivariate platform was used to examine
how many variables relate to each other. For each correlation,
the correlation coeﬃcient (Spearman’s ρ) and P-value were
obtained. The correlation coeﬃcient values ranged from –1 to
+1 with larger absolute values indicating stronger relationship
while positive and negative values indicating the direction of
association. Alpha value for the correlation conﬁdence intervals
was set up as 0.05.
RESULTS
Changes in Metabolic Biomarkers
The results of blood glucose, blood pressure, body weight,
waist circumference, and BMI were consistent with the results
of parallel study that included 30 subjects and focused on
examining the blood cholesterol lowering eﬀects of β-glucan
(Supplementary Table 1 and Wang et al., 2016). The only
exception was the TC levels, which was reduced by 3 g HMW
β-glucan in the parallel study but not in the sub-set of 19
individuals subjected to microbiome analysis.
Changes in α- and β-Diversity
Alpha-diversity indices of fecal microbiota, or the diversity within
a community, did not change in response to consumption of
β-glucan (Table 1). In contrast, β-diversity of the fecal microbial
community, or the dissimilarity between communities, measured
by weighted UniFrac was aﬀected by β-glucan supplementation
(P = 0.002, PERMANOVA, Supplementary Figure 1). In
the pairwise comparison, signiﬁcant diﬀerences were observed
among microbial communities between 3 g HMW and 3 g
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TABLE 1 | Biodiversity of microbial communities in feces affected by β-glucan diets.
Alpha-diversity1 Diet2 SEM3 P-value4
WR Control 3 g LMW 5 g LMW 3 g HMW
Chao1 2502 2594 2548 2730 122 0.22
Good’s coverage 0.85 0.84 0.84 0.83 0.01 0.14
Observed species 865 893 881 931 33 0.16
Shannon 7.45 7.54 7.51 7.68 0.19 0.36
Simpson 0.98 0.98 0.98 0.98 0.003 0.58
1Chao1 and Good’s coverage are the richness indices; Shannon and Simpson are diversity estimators.
2Diets include: Wheat and rice control (WR Control), 3 g/d low molecular weight barley β-glucan (3 g LMW), 5 g/d low molecular weight barley β-glucan (5 g LMW), 3 g/d
high molecular weight barley β-glucan (3 g HMW). Data are presented as mean values.
3SEM, standard error of means.
4P-values are shown for the diet effect between groups analyzed by mixed model ANCOVA with period and the interaction of period × diet as fixed factors.
LMW β-glucan (P = 0. 014, Figure 1C), 3 g HMW β-glucan
and the control (P = 0. 011, Figure 1E), and 5 g LMW
β-glucan and the control (P = 0. 044, Figure 1F). The diﬀerences
between 5 g LMW and 3 g HMW β-glucan (Figure 1A),
5 g LMW and 3 g LMW β-glucan (Figure 1B), 3 g LMW
β-glucan and control (Figure 1D) were not signiﬁcant. The
community composition proﬁle of the above-mentioned three
paired comparisons, which showed signiﬁcant diﬀerences in their
β-diversity, were further compared using PLS-DA as discussed
below (Figure 2).
Compositional Shifts in Bacterial
Communities
While majority of OTUs were identiﬁed at the genus level,
some were only classiﬁed at the phylum (p.), class (c.),
order (o.), or family (f.) levels. Across all samples, 11
bacterial phyla were identiﬁed of which two phyla Firmicutes
and Bacteroidetes were abundant (above 1% of community),
accounting for approximately 84 and 9% of the entire bacterial
community, respectively. Another four bacterial phyla, including
Actinobacteria, Verrucomicrobia, Proteobacteria, and Tenericute
were present at abundances between 0.1 and 1% of the
community (Table 2). The remaining ﬁve phyla including
Cyanobacteria, Synergistetes, Lentisphaerae, Deferribacteres, and
Elusimicrobia were in low abundance (<0.1% of community).
Abundances of p. Firmicutes and Bacteroidetes were signiﬁcantly
impacted in response to 3 g/d HMW β-glucan consumption,
where Firmicutes decreased (77.91% for 3 g HMW β-glucan
vs. 89.69% for control, P < 0.001) and Bacteroidetes increased
(14.22% for 3 g HMWβ-glucan vs. 4.99% for control, P < 0.001)
compared to the control (Table 2). However, Firmicutes and
Bacteroidetes abundances did not change in response to 5 g/d
LMW and 3 g/d LMW β-glucan consumption. The abundances
of p. Actinobacteria, Verrucomicrobia, Proteobacteria, and
Tenericute did not change across all treatments.
At the lower taxonomical level and across all samples, 169
distinct bacterial taxa were detected of which 44 had a relative
abundance above 0.1% of community (Table 3). Of these 44
taxa, 24 were identiﬁed at the genus level, 14 at the family level,
four at the order level, and two at the class level. Irrespective of
treatment group, g. Bacteroides was the most abundant genera
in p. Bacteroidetes, whereas p. Firmicutes were dominated by
g. Blautia. Consumption of 3 g/d HMW β-glucan increased
the abundances of Bacteroides (12.26% vs. 5.96%, P = 0.002)
compared to control. Consumption of 3 g/d HMW β-glucan also
increased the relative abundance of o. Bacteroidales compared
to the 3 g LMW β-glucan treatment (0.24 vs. 0.12%, P = 0.04).
Moreover, f. Rikenellaceae and g. Prevotella showed increasing
trends (P < 0.1) following 3 g/d HMW β-glucan consumption
compared to control (Table 3). In contrast, g. Streptococcus (p.
Firmicutes) was signiﬁcantly decreased by 3 g/d HMW β-glucan
compared to control (0.035% vs. 0.27%, P = 0.02). Additionally,
g.Dorea showed a decreasing trend (P < 0.1) in response to 3 g/d
HMW β-glucan consumption (Table 3).
The PLS-DA results (given for the cut-oﬀ VIP value of 0.5)
supported the SAS output, however, due to the higher sensitivity
of PLS-DA methodology, additional signiﬁcant diﬀerences
among treatments, especially in low abundance taxa, were
identiﬁed. For instance, when comparing 3 g HMW β-glucan vs.
control, two additional low abundance taxa, g. Collinsella and o.
Lactobacillales, were identiﬁed to be positively associated with
control (Figure 2A).
Correlations Between the Altered
Bacterial Taxa and CVD Risk Factors
Spearman non-parametric correlation was conducted to test
the association between bacterial taxa and risk factors of
CVD (Table 4). Weak (Spearman’s ρ between 0.20 and 0.39)
and moderate correlations (Spearman’s ρ between 0.40 and
0.59) were observed between parameters associated with CVD
including BMI, waist circumference, TC levels, LDL-C, HDL-C,
TG, glucose, systolic and diastolic blood pressure, and speciﬁc
members of bacterial community (Table 4). Bacteria, which were
aﬀected by 3 g HMW β-glucan and also showed correlation
with parameters associated with CVD, were g. Bacteroides which
was negatively correlated with waist circumference (Spearman’s
ρ = –0.25; P = 0.03) and diastolic BP (Spearman’s ρ = –0.28;
P = 0.01); g. Prevotella which showed negative correlation with
TG (Spearman’s ρ = -0.25; P = 0.02); and g. Dorea which was
positively associated with BMI (Spearman’s ρ = 0.27; P = 0.01),
waist circumference (Spearman’s ρ = 0.31; P = 0.008) and
diastolic BP (Spearman’s ρ = 0.28; P = 0.01).
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FIGURE 1 | Principal coordinates analysis (PCoA) of weighted UniFrac distances. Between community diversity among stool samples was tested for the
impact of β-glucan amount and MW on the clustering patterns of microbiota in (A) 5 g LMW vs. 3 g HMW (P = 0.35), (B) 3 g LMW vs. 3 g HMW (P = 0.13), (C) 3 g
LMW vs. 3 g HMW (P = 0.014), (D) 3 g LMW vs. Control (P = 0.53), (E) 3 g HMW vs. Control (P = 0.011), (F) 5 g LMW vs. Control (P = 0.044). Symbols with
different colors represent samples belonging to individuals under specific treatment. For each comparison, the P-value was obtained from PERMANOVA and
considered significant for P < 0.05.
Prediction of Functional and Metabolic
Capacity of Gut Microbiota
A total of 41 level 2 and 328 level 3 KOs were identiﬁed for the
fecal microbiota (Supplementary Tables 2 and 3). Diﬀerences in
metabolic potentials of gut microbiota among treatments were in
line with OTU based diﬀerences observed with weighted UniFrac
(Figure 3). Predicted shifts in glycerolipid metabolism and
other glycan degradation were increased by 3 g HMW β-glucan
compared with control (P = 0.026 and P = 0.021, respectively;
Figure 3A). Same results for glycerolipid metabolism and other
glycan degradation were observed when compare 3 g HMW vs.
3 g LMW β-glucan (P = 0.013 and P = 0.002, respectively;
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FIGURE 2 | Partial least square discriminant analysis (PLS-DA) loading plot. The PLS-DA graphs were generated based on the relative abundance of the
putative bacterial genera in stool samples and their association with (A) 3 g HMW or control diet, (B) 3 g HMW or 3 g LMW diet, and (C) 5 g LMW or control diet. –
or + signs and their color are indicative of significant negative or positive associations between each taxa and the associated treatment.
Frontiers in Microbiology | www.frontiersin.org 7 February 2016 | Volume 7 | Article 129
Wang et al. Impact of β-Glucan on Human Gut Microbiota
TABLE 2 | Relative abundances of bacterial phyla in feces after β-glucan intervention.
Phylum1 Diet2 SEM3 P-value
Control 3 g LMW 5 g LMW 3 g HMW
Above 1 % of community
Bacteroidetes 4.99a 7.59a 9.95ab 14.22b 1.67 <0.0014
Firmicutes 89.69a 87.50a 82.36ab 77.91b 2.16 <0.0014
Between 0.1 and 1% of community
Actinobacteria 0.64 0.71 1.07 0.55 0.25 0.335
Proteobacteria 0.18 0.10 0.14 0.32 0.13 0.665
Tenericutes 0.086 0.066 0.093 0.19 0.06 0.475
Verrucomicrobia 0.14 0.39 0.19 0.39 0.17 0.285
a,bMeans within the same row with different superscripts are different (P < 0.05).
1Only phyla with abundances greater than 0.1% of the community (at least in one of the treatment group) are presented. Additional phyla including Cyanobacteria,
Synergistetes, Lentisphaerae, Deferribacteres, Elusimicrobia were present in abundances below 0.1% of the community.
2Diets include: Wheat and rice control (Control), 3 g/d low molecular weight barley β-glucan (3 g LMW), 5 g/d low molecular weight barley β-glucan (5 g LMW), 3 g/d
high molecular weight barley β-glucan (3 g HMW). Data are presented as mean values.
3SEM, Standard Error of Mean.
4P-values are shown for the diet effect between groups analyzed by mixed model ANCOVA with diet, period, period × diet as fixed factors.
5P-values are shown for the diet effect between groups analyzed by GLIMMIX procedure of SAS with diet, period, period × diet as fixed factors.
Figure 3B). However, although 5 g LMW β-glucan showed
diﬀerences in weighted UniFrac compared with control, only
three metabolisms (phenylpropanoid biosynthesis, cyanoamino
acids metabolism, and glycosaminoglycan degradation) were
predicted to be diﬀerent using PICRUSt (Figure 3E), whereas
no diﬀerences were observed between 3 g LMW β-glucan and
control with both weighted UniFrac or PICRUSt (no diﬀerence
to be graphed).
DISCUSSION
The main ﬁnding of this controlled feeding study was that
gut microbiota were modulated in response to barley β-glucan
consumption on a MW-dependent manner, and that the shifts
in gut microbiota was correlated with reduced CVD risk factors.
Speciﬁcally, consumption of 3 g/d HMW β-glucan resulted
in increased abundance of p. Bacteroidetes and decreased
abundance of p. Firmicutes, as did several of their respective taxa
at the lower taxonomical levels (Tables 2 and 3). The shifts in
g. Bacteroides, Prevotella, and Dorea were favorably correlated
with an improved CVD risk factor proﬁle, such as BMI, waist
circumference, TG, blood pressure (Table 4). Consumption of
5 g/d LMW β-glucan only impacted the β-diversity but not the
composition of gut microbiota compared to control (Figure 1F,
Tables 2 and 3). Additionally, the consumption of 3 g/d LMW
β-glucan failed to alter either the β-diversity or the composition
of gut microbiota.
Previous in vitro fermentation and in vivo intervention
studies have been conducted examining the ability of β-glucan
to alter microbiota, however, conclusions were obscure leaving
the breadth of the research inadequate (Crittenden et al., 2002;
Dongowski et al., 2002; Hughes et al., 2008; Pieper et al., 2008;
Mitsou et al., 2010). This was partially due to the inconsistencies
in study design, experimental models and methodologies used
for bacterial community analyses, e.g., quantitative PCR and
ﬂuorescence in site hybridization (FISH) that can only monitor
selected members of the bacterial community. In the present
research, we used a randomized controlled human trial that is
considered gold standard for a clinical study. Furthermore, we
employed 16S rRNA gene sequencing for bacterial community
proﬁling, which is superior over previously used methods
(AbuMweis et al., 2010b; Gilbert and Dupont, 2011).
Our results support that modulation in gut microbiota
following barley β-glucan consumption is dependent on β-glucan
MW as bacterial communities more profoundly shifted in
response to diet containing 3 g HMW β-glucan. To date, there are
few studies that have investigated the impact of physicochemical
properties of β-glucan on microbiota composition. In an in vitro
batch culture study, Hughes et al. (2008) assessed the impact of
barley and oat derived β-glucan with diﬀerentMW levels (average
MW 130, 172, 243 kDa for barley β-glucan and 150, 230 kDa for
oat β-glucan) on fecal microbiota using FISH and concluded that
the Bacteroides-Prevotella group increased from baseline with all
but the 243 kDa barley and 230 kDa oat substrates. Unfortunately,
the β-glucan MW levels tested in the abovementioned study did
not include ideal representatives of “high” MW β-glucan that
could result in physiological beneﬁts attributed to this compound
(Tosh et al., 2008; Wolever et al., 2010). For instance, it has been
shown that β-glucan with MW lower than 210 kDa fails to lower
cholesterol levels (Wolever et al., 2010). Thus, the tested range
of 150–243 kDa in the Hughes et al. (2008) study is considered
very low MW and no true “high” MW level was examined. In
our study, we selected the low and high MW β-glucan (288
and 1349 kDa, respectively) on the basis of cholesterol-lowering
capability of this compound (Wolever et al., 2010).
The HMW β-glucan increases the viscosity of digesta (Tosh
et al., 2010) in the GI tract, which is believed to slow down
digesta transit time (Dikeman and Fahey, 2006; Lattimer and
Haub, 2010). Consequently, the slower transit time may allow
for prolonged exposure of fermentable compounds to microbial
community (Koropatkin et al., 2012), possibly resulting in
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TABLE 3 | Relative abundances of bacterial genera in feces after β-glucan intervention.
Phyla Taxa1 Diet2 SEM3 P-value
Control 3 g LMW 5 g LMW 3 g HMW
Actinobacteria g. Bifidobacterium 1.033 1.00 1.24 0.67 0.30 0.574
Bacteroidetes
g. Bacteroides 5.96a 6.31ab 8.30ab 12.26b 1.60 0.0024
f. Rikenellaceae 0.75 1.15 1.24 1.76 0.41 0.055
g. Prevotella 0.48 0.54 1.46 1.84 0.71 0.095
f. [Barnesiellaceae] 0.11 0.2 0.31 0.57 0.19 0.375
g. Parabacteroides 0.17 0.14 0.18 0.23 0.054 0.625
o. Bacteroidales 0.17ab 0.12a 0.21ab 0.24b 0.065 0.045
f. Bacteroidaceae 0.079 0.13 0.12 0.15 0.14 0.325
Firmicutes
g. Blautia 11.43 9.31 11.55 8.5 1.78 0.354
g. Coprococcus 9.11 9.17 8.21 7.95 1.51 0.834
g. Ruminococcus 6.18 6.83 5.82 4.8 0.92 0.214
f. Lachnospiraceae unclassified 6.77 6.48 7.22 7.29 0.84 0.724
f. Ruminococcaceae 4.63 4.32 3.34 4.04 0.78 0.414
g. Faecalibacterium 5.34 4.71 3.92 4.32 1.57 0.175
f. Ruminococcaceae 3.12 2.85 1.97 2.98 0.82 0.504
f. Coprobacillaceae 2.45 2.91 3.31 2.91 0.66 0.554
g. Roseburia 1.75 2.73 2.74 2.26 0.55 0.284
g. [Ruminococcus] 3.43 2.86 2.99 2.76 0.58 0.494
g. Oscillospira 1.56 1.62 1.29 1.48 0.48 0.824
c. Clostridia unclassified 2.91 2.64 2.87 2.58 0.30 0.634
o. Clostridiales 1.28 1.24 1.06 1.3 0.20 0.704
g. Dialister 0.46 0.3 0.23 0.24 0.21 0.535
f. Christensenellaceae 0.05 0.33 0.14 0.17 0.17 0.775
g. Dorea 1.01 0.81 0.77 0.65 0.14 0.074
g. Lachnospira 0.4 0.46 0.36 1.06 0.22 0.185
f. Peptostreptococcaceae 0.34 0.67 0.47 0.26 0.19 0.474
f. Lachnospiraceae 0.43 0.43 0.31 0.69 0.19 0.544
f. Catabacteriaceae 0.42 0.61 0.35 0.81 0.50 0.274
g. Catenibacterium 0.3 0.56 0.73 0.35 0.37 0.234
c. Clostridia 0.14 0.17 0.13 0.17 0.04 0.634
o. Clostridiales unclassified 0.098 0.27 0.28 0.11 0.14 0.864
g. [Eubacterium] 0.15 0.12 0.11 0.11 0.12 0.984
p. Firmicutes unclassified 0.25 0.24 0.26 0.21 0.032 0.394
f. [Coprobacillaceae] unclassified 0.2 0.29 0.32 0.23 0.12 0.905
f. Clostridiaceae unclassified 0.11 0.12 0.091 0.15 0.09 0.975
g. Clostridium 0.097 0.14 0.084 0.12 0.08 0.965
g. Turicibacter 0.056 0.079 0.043 0.066 0.07 0.985
g. Streptococcus 0.27a 0.14ab 0.043ab 0.035b 0.07 0.025
Proteobacteria
f. Enterobacteriaceae unclassified 0.12 0.011 0.18 0.54 0.19 0.095
Tenericutes
o. RF39 0.082 0.062 0.085 0.17 0.058 0.525
Verrucomicrobia
g. Akkermansia 0.14 0.38 0.19 0.39 0.17 0.285
a,bMeans within the same row with different superscripts are different (P < 0.05).
1Some sequences were only affiliated to phylum (p.), class (c.), order (o.), family (f.), or genus (g.) levels.
2Diets include: Wheat and rice control (Control), 3 g/d low molecular weight barley β-glucan (3 g LMW), 5 g/d low molecular weight barley β-glucan (5 g LMW), 3 g/d
high molecular weight barley β-glucan (3 g HMW). Data are presented as mean values.
3SEM, Standard Error of Mean.
4P-values are shown for the diet effect between groups analyzed by mixed model ANCOVA with diet, period, period × diet as fixed factors.
5P-values are shown for the diet effect between groups analyzed by GLIMMIX procedure of SAS with diet, period, period × diet as fixed factors.
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TABLE 4 | Non-parametric correlations between metabolic parameters and bacterial taxa.
Metabolic parameters1 Taxa2 Phyla Abundance3 Spearman’s ρ4 P-value5
BMI g. Turicibacter Firmicutes 0.16 −0.46 <0.0001
g. Catenibacterium Firmicutes 0.39 0.31 0.007
f.[Barnesiellaceae] Bacteroidetes 0.46 0.26 0.02
f. Lachnospiraceae Firmicutes 0.59 −0.21 0.07
g. Dorea Firmicutes 0.90 0.27 0.01
f. Ruminococcaceae Firmicutes 6.56 −0.28 0.01
g. Faecalibacterium Firmicutes 6.84 0.23 0.04
g. Ruminococcus Firmicutes 7.48 −0.27 0.01
g. Bacteroides Bacteroidetes 8.59 −0.20 0.08
Waist circumference g. Turicibacter Firmicutes 0.16 −0.47 <0.0001
g. Parabacteroides Bacteroidetes 0.19 −0.21 0.07
g. [Eubacterium] Firmicutes 0.27 0.27 0.02
g. Catenibacterium Firmicutes 0.39 0.25 0.03
f. Lachnospiraceae Firmicutes 0.59 −0.24 0.04
g. Dorea Firmicutes 0.90 0.31 0.008
g. Faecalibacterium Firmicutes 6.84 0.21 0.07
g. Bacteroides Bacteroidetes 8.59 −0.25 0.03
Total cholesterol g. [Ruminococcus] Firmicutes 3.38 −0.29 0.01
g. Roseburia Firmicutes 3.43 −0.24 0.04
f. Ruminococcaceae Firmicutes 6.56 0.24 0.03
g. Ruminococcus Firmicutes 7.48 0.32 0.005
LDL cholesterol g. [Eubacterium] Firmicutes 0.27 0.20 0.08
g. [Ruminococcus] Firmicutes 3.38 −0.33 0.004
f. Ruminococcaceae Firmicutes 6.56 0.29 0.01
f. Lachnospiraceae unclassified Firmicutes 7.37 −0.30 0.009
g. Ruminococcus Firmicutes 7.48 0.30 0.009
g. Blautia Firmicutes 11.27 −0.24 0.03
Triglyceride f. Enterobacteriaceae Unclassified Proteobacteria 0.18 0.25 0.03
g. Parabacteroides Bacteroidetes 0.19 −0.25 0.02
f. Clostridiaceae unclassified Firmicutes 0.24 0.34 0.002
f. Catabacteriaceae Firmicutes 0.43 −0.24 0.04
f. Peptostreptococcaceae Firmicutes 0.66 −0.28 0.01
f. Christensenellaceae Firmicutes 0.96 −0.38 0.0007
g. Dialister Firmicutes 1.06 0.25 0.03
g. Prevotella Bacteroidetes 1.09 −0.25 0.02
g. Oscillospira Firmicutes 3.02 −0.33 0.004
f. Ruminococcaceae Firmicutes 6.56 −0.26 0.02
f. Lachnospiraceae unclassified Firmicutes 7.37 0.24 0.03
HDL cholesterol g. Turicibacter Firmicutes 0.16 0.37 0.001
g. [Eubacterium] Firmicutes 0.27 −0.26 0.02
g. Dorea Firmicutes 0.90 −0.22 0.05
g. Dialister Firmicutes 1.06 −0.26 0.02
g. Roseburia Firmicutes 3.43 −0.26 0.02
g. Faecalibacterium Firmicutes 6.84 −0.31 0.006
g. Ruminococcus Firmicutes 7.48 0.26 0.02
Glucose f. Peptostreptococcaceae Firmicutes 0.66 −0.25 0.03
g. Dialister Firmicutes 1.06 −0.21 0.07
c. Clostridia unclassified Firmicutes 2.95 −0.21 0.06
Systolic BP f. Catabacteriaceae Firmicutes 0.43 0.36 0.001
f. Peptostreptococcaceae Firmicutes 0.66 −0.28 0.01
g. Bifidobacterium Actinobacteria 0.95 −0.24 0.04
g. Roseburia Firmicutes 3.43 −0.34 0.003
g. Bacteroides Bacteroidetes 8.59 −0.24 0.04
(Continued)
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TABLE 4 | (Continued)
Metabolic parameters1 Taxa2 Phyla Abundance3 Spearman’s ρ4 P-value5
Diastolic BP g. Turicibacter Firmicutes 0.16 −0.34 0.003
p. Firmicutes unclassified Firmicutes 0.27 0.27 0.02
g. [Eubacterium] Firmicutes 0.27 0.29 0.01
f. Catabacteriaceae Firmicutes 0.43 0.32 0.007
f. Lachnospiraceae Firmicutes 0.59 −0.32 0.006
g. Dorea Firmicutes 0.90 0.28 0.01
g. Bacteroides Bacteroidetes 8.59 −0.28 0.01
1Anthropometrics, biochemical markers and blood pressure collected at the end of the intervention: BMI, body mass index; LDL, low-density lipoprotein; HDL, high-
density lipoprotein; BP, blood pressure.
2Some sequences were only affiliated to phylum (p.), class (c.), order (o.), family (f.), or genus (g.) levels.
3Abundance is shown for the composition of bacterial taxa in percentage (%).
4Non-parametric Spearman’s rank correlation coefficient.
5P-values are shown for the probability of the Spearman’s correlation.
alteration of gut microbiota by HMW β-glucan observed in
this study. Additionally, genes associatedwith glycosaminoglycan
degradation and other glycan degradation were at higher
abundance in the predicted metagenome with diet containing
3 g HMW β-glucan compared to the control (Figure 3A)
indicating that certain members of the bacterial community,
such as members of p. Bacteroidetes, had taken advantage of
HMW β-glucan and perhaps other fermentable substrates in
the digesta most likely due to increased exposure time for
microbial fermentation. Lending support to this hypothesis, a
recent study (El Kaoutari et al., 2013) examined the carbohydrate-
digestive capacity of a simpliﬁed mini-microbiome, which was
representative of human gut microbiome. Authors reported
that members of p. Bacteroidetes had higher mean glycoside
hydrolases (GHs) and polysaccharide lyases (PLs) genes per
genome as well as signal peptide-containing GHs and PLs
compared to the members of p. Firmicutes and any other
bacterial phyla in the human gut. Authors further suggest that
members of p. Bacteroidetes are likely the primary degraders
of the many complex polysaccharides in the plant cell wall due
to grater range of GHs and PLs that are not present or poorly
represented in members of other gut bacterial phyla. This further
supports our ﬁndings that members of p. Bacteroidetes have a
competitive advantage in presence of HMW β-glucan that has
higher glycosidic bonds compared to LMW β-glucan.
The observed changes in microbial community at the phylum
level in response to 3 g/d HMW β-glucan were similar to
the microbiota proﬁle in “lean” individuals. Ley et al. (2006)
described that the relative proportion of Bacteroidetes is
decreased in obese people compared with lean people, and this
proportion also increased with diet-induced weight loss. Similar
to the microbiota proﬁle of lean individuals, consumption of
3 g/d HMW β-glucan increased the Bacteroidetes and decreased
the Firmicutes abundance, suggesting that consumption of
HMW β-glucan may promote the healthy balance of microbiota
in the gut (Ley et al., 2006). In the present study, weight
loss was not observed in response to 3 g/d HMW β-glucan
consumption most likely due to controlled study design, which
intended to maintain body weight. To examine and interpret the
potential weight loss eﬀects of β-glucan consumption, further
research with a speciﬁc study design aiming at the correlation
between β-glucan consumption, microbiota shifts, and weight
management is required.
The present intervention study showed that consuming
3 g/d of HMW β-glucan was able to signiﬁcantly increase g.
Bacteroides and moderately increase g. Prevotella in a short-
term intervention of 35 days. The increased in g. Bacteroides
were negatively correlated with BMI, waist circumferences and
blood pressure (Table 4). Genus Prevotella, however, showed
a negative correlation with TG. Additionally, g. Dorea that
tended to be decreased by 3 g/d HMW β-glucan was positively
associated with BMI, waist circumferences and diastolic blood
pressure. Consumption of 3 g/d HMW β-glucan also decreased
g. Streptococcus compared to the control. But this genus was not
correlated with biochemical markers, anthropometric markers or
blood pressure that weremeasured in the clinical trial. Altogether,
these results suggested that consumption of 3 g/d HMW β-glucan
for 35 days was able to alter the gut microbiota and the altered
microbiota were correlated with a favorable shift in parameters
associated with CVD. However, since these metabolic parameters
were not changed signiﬁcantly in the sampled subjects (n = 19),
studies with greater sample size would be beneﬁcial to further
investigate the causality to see whether the altered gut microbiota
improves the CVD risk factors.
In addition, predicted metabolic capacity of bacterial
community (generated using PICRUSt) exhibited increased
abundances of genes associated with glycerolipid metabolism
with HMW β-glucan diet compared to control and LMW
β-glucan diets, which has been associated with obesity and type
2 diabetes via energy homeostasis, appetite control, and insulin
sensitivity (Prentki and Madiraju, 2008). These observations
indicated that HMW β-glucan-induced gut microbial shifts may
lead to reduced CVD risk and shifts the glycerolipid metabolism
via an increased Bacteroidetes:Firmicutes ratio. That being said,
we should take into account that PICRUSt predictions are based
on known functions of the microbial communities present in
the human GI tract obtained from the metagenomic studies.
These predictions need to be conﬁrmed using whole genome
shotgun DNA (metagenomics) or RNA (metatranscriptomics)
sequencing of analyzed samples.
Gut health in part is associated with proper richness,
diversity and stability of gut microbiome. Recent research shows
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FIGURE 3 | Fold change in the number of 16S rRNA sequences annotated to KEGG level 3 orthologies representing the predicted metabolic capacity
of the gut microbiome. (A) 3 g HMW compared to control diet, (B) 3 g HMW compared to 3 g LMW diet, and (C) 3 g HMW compared to 5 g LMW diet, (D) 3 g
LMW compared to 5 g LMW diet, and (E) 5 g LMW compared to control diet.
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that individuals with low richness of microbiota are more
vulnerable to obesity, insulin resistance and dyslipidemia
compared to those with high richness of microbiota (Le Chatelier
et al., 2013). In this study, the α-diversity of microbiota did
not change by β-glucan consumption. β-diversity of microbiota,
however, was impacted but the diﬀerences in β-diversity among
treatments were signiﬁcant when determined using weighted
UniFrac distances rather than unweighted UniFrac distances,
suggesting that β-glucan’s impact was through changing the
abundance of certain members of the microbial community but
not their presence and/or absence. As such, we believe that
potential health beneﬁt resulted from consumption of HMW
β-glucan is via increase in the abundance of certain members of
bacterial community but not community richness.
Overall, our results suggest that β-glucan with higher MW
was able to alter the gut microbiota and the shifts observed were
positively associated with an improved CVD risk factor proﬁle.
Although studies with large samples size are needed to conﬁrm
the relationship between the altered gut microbiota by β-glucan
and the improved CVDhealth beneﬁts, results from current study
are reminiscent of the hypothesis that altering gut microbiota
is responsible for the physiological beneﬁts of HMW β-glucan
consumption.
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